Testing and treating newborns for spinal muscular atrophy: saving lives and healthcare costs
Published on the 03 August 2021
Gene therapy for spinal muscular atrophy might have a high up-front price tag. But by screening and treating infants early, the therapy can save both lives and money in the long term.
By the time an infant with SMA starts showing symptoms, they've already lost 90 per cent of their nerves – which is why early detection and treatment is so important
